Common Stock, $0.001 par value
- Symbol
- CYTK
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Cytokinetics, Incorporated
CYTKNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On August 28, 2026, Cytokinetics, Incorporated issued a press release announcing its presentation of the full results of ACACIA-HCM at the European Society of Cardiology (ESC) Congress 2026 and published in the New England Journal of Medicine.…
Company context
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the approved in the U.S., China, European Union and United Kingdom for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
Current securities
Registered securities in this filing
Cytokinetics, Incorporated · 8-K · Filed 2026-08-28
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On August 28, 2026, Cytokinetics, Incorporated issued a press release announcing its presentation of the full results of ACACIA-HCM at the European Society of Cardiology (ESC) Congress 2026 and published in the New England Journal of Medicine. The full text of the press release issued in connection with this announcement is incorporated herein as Exhibit 99.1 to this Current Report on Form 8-K.
Filed exhibits (1)
EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, and simultaneously published in The New England Journal of Medicine. 1 ACACIA-HCM…
Open exhibit ↗